-- 据周四提交给澳大利亚证券交易所的文件显示，Radiopharm Theranostics（ASX：RAD）已完成美国2b期影像学试验的最后一名患者的给药。该试验旨在评估氟-18-RAD101在30名确诊为不同来源实体瘤复发性脑转移患者中的诊断性能。 该研究的主要目标是评估氟-18-RAD101阳性病灶与常规影像学检查（钆增强磁共振成像）所见病灶的一致性，研究对象为疑似复发性脑转移患者。 RAD101是一种新型成像小分子，靶向脂肪酸合成酶（FASN）。FASN是一种多酶蛋白，可催化脂肪酸合成，并在许多实体瘤中过度表达。
Related Articles
Asia
Correction: Ningbo Joyson Electronic's Q1 Profit Climbs 18%
(Corrects period in first paragraph to first quarter of 2026)Ningbo Joyson Electronic (HKG:0699, SHA:600699) recorded an 18% rise in attributable profit in the first quarter of 2026 to 402.1 million yuan from 340.5 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share increased to 0.26 yuan from 0.24 yuan in the corresponding period of the previous fiscal year.Operating income slipped 5.2% to 13.8 billion yuan from 14.6 billion yuan in the year-ago period.
$HKG:0699$SHA:600699
Mining & Metals
Greenland Resources Providing Update on EUR 50 Equity Investment Led by Horizon Eur
$MOLY.TO
Asia
Ningbo Joyson Electronic's Q1 Profit Climbs 18%
Ningbo Joyson Electronic (HKG:0699, SHA:600699) recorded an 18% rise in attributable profit in the first quarter of 2025 to 402.1 million yuan from 340.5 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share increased to 0.26 yuan from 0.24 yuan in the corresponding period of the previous fiscal year.Operating income slipped 5.2% to 13.8 billion yuan from 14.6 billion yuan in the year-ago period.
$HKG:0699$SHA:600699